Terms: = Kidney tumors AND SETD2, ENSG00000181555, 29072 AND Treatment
39 results:
1. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Borkowetz A; Sommer U; Baretton G; Gruellich C; Bürk BT; Erb HHH; Thomas C;
World J Urol; 2024 Feb; 42(1):94. PubMed ID: 38386122
[TBL] [Abstract] [Full Text] [Related]
2. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
[TBL] [Abstract] [Full Text] [Related]
3. Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis.
Tariki MS; Barberan CCG; Torres JA; Ruano APC; Ferreira Costa DJ; Braun AC; da Silva Alves V; de Cássio Zequi S; da Costa WH; Fay AP; Torrezan G; Carraro DM; Domingos Chinen LT
Pathol Res Pract; 2024 Jan; 253():154918. PubMed ID: 37995423
[TBL] [Abstract] [Full Text] [Related]
4. Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Lu X; Vano YA; Su X; Helleux A; Lindner V; Mouawad R; Spano JP; Rouprêt M; Compérat E; Verkarre V; Sun CM; Bennamoun M; Lang H; Barthelemy P; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Cell Rep Med; 2023 Nov; 4(11):101287. PubMed ID: 37967556
[TBL] [Abstract] [Full Text] [Related]
5. setd2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in kidney Cancer.
Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
[TBL] [Abstract] [Full Text] [Related]
6. setd2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
Liu XD; Zhang YT; McGrail DJ; Zhang X; Lam T; Hoang A; Hasanov E; Manyam G; Peterson CB; Zhu H; Kumar SV; Akbani R; Pilie PG; Tannir NM; Peng G; Jonasch E
Clin Cancer Res; 2023 Oct; 29(19):4002-4015. PubMed ID: 37527013
[TBL] [Abstract] [Full Text] [Related]
7. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
8. Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.
Cotta BH; Choueiri TK; Cieslik M; Ghatalia P; Mehra R; Morgan TM; Palapattu GS; Shuch B; Vaishampayan U; Van Allen E; Ari Hakimi A; Salami SS
Eur Urol; 2023 Aug; 84(2):166-175. PubMed ID: 37085424
[TBL] [Abstract] [Full Text] [Related]
9. RNA mis-splicing drives viral mimicry response after DNMTi therapy in setd2-mutant kidney cancer.
Li HT; Jang HJ; Rohena-Rivera K; Liu M; Gujar H; Kulchycki J; Zhao S; Billet S; Zhou X; Weisenberger DJ; Gill I; Jones PA; Bhowmick NA; Liang G
Cell Rep; 2023 Jan; 42(1):112016. PubMed ID: 36662621
[TBL] [Abstract] [Full Text] [Related]
10. Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma.
Deng Y; Guo K; Tang Z; Feng Y; Cai S; Ye J; Xi Y; Li J; Liu R; Cai C; Tan Z; Zhang Y; Han Z; Zeng G; Zhong W
Front Immunol; 2022; 13():1046790. PubMed ID: 36505457
[TBL] [Abstract] [Full Text] [Related]
11. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract] [Full Text] [Related]
12. Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Urol Oncol; 2023 Jan; 41(1):51.e13-51.e23. PubMed ID: 36328922
[TBL] [Abstract] [Full Text] [Related]
13. The convergence of tumor suppressors on the type I interferon pathway in clear cell renal cell carcinoma and its therapeutic implications.
Langbein LE; El Hajjar R; Kim WY; Yang H
Am J Physiol Cell Physiol; 2022 Nov; 323(5):C1417-C1429. PubMed ID: 36154696
[TBL] [Abstract] [Full Text] [Related]
14. Development of a setd2-related immune prognostic signature in clear cell renal cell carcinoma.
Wang X; Xia Z; Li Z; Zhang C
Medicine (Baltimore); 2022 Aug; 101(31):e29561. PubMed ID: 35945780
[TBL] [Abstract] [Full Text] [Related]
15. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract] [Full Text] [Related]
16. Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for Prognosis and Immunotherapy.
Lin E; Zhu P; Ye C; Huang M; Liu X; Tian K; Tang Y; Zeng J; Cheng S; Liu J; Liu Y; Yu Y
Front Immunol; 2022; 13():830220. PubMed ID: 35677048
[TBL] [Abstract] [Full Text] [Related]
17. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract] [Full Text] [Related]
18. T and NK cell abundance defines two distinct subgroups of renal cell carcinoma.
Lee MH; Järvinen P; Nísen H; Brück O; Ilander M; Uski I; Theodoropoulos J; Kankainen M; Mirtti T; Mustjoki S; Kreutzman A
Oncoimmunology; 2022; 11(1):1993042. PubMed ID: 35003893
[TBL] [Abstract] [Full Text] [Related]
19. Complete Pathologic Response to Pembrolizumab and Axitinib in a Patient With Sarcomatoid RCC and Ocrelizumab-Treated Multiple Sclerosis.
Neuzil K; Gessner K; Hedgepeth J; Wobker SE; Wallen EM; Morgan KP; Bjurlin MA; Rose TL
Urology; 2022 Jun; 164():50-54. PubMed ID: 34973243
[TBL] [Abstract] [Full Text] [Related]
20. Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis.
Mano R; Duzgol C; Ganat M; Goldman DA; Blum KA; Silagy AW; Walasek A; Sanchez A; DiNatale RG; Marcon J; Kashan M; Becerra MF; Benfante NE; Coleman JA; Kattan MW; Russo P; Akin O; Ostrovnaya I; Hakimi AA
Urol Oncol; 2021 Nov; 39(11):791.e17-791.e24. PubMed ID: 34580025
[TBL] [Abstract] [Full Text] [Related]
[Next]